Heudorf Ursel, Kowall Bernd
Institute of Hygiene and Environmental Medicine, Justus Liebig University, Gießen, Germany.
Institute for Medical Informatics, Biometry and Epidemiology, University Hospital, Essen, Germany.
GMS Hyg Infect Control. 2025 Mar 4;20:Doc04. doi: 10.3205/dgkh000533. eCollection 2025.
Mortality during the SARS-CoV-2 pandemic was studied in many countries. The results were strongly influenced by the chosen calculation method, the adjustment to the ageing of the population and the reference periods used. Smaller-scale studies sometimes showed considerable differences within countries, but it is unclear whether the differences within a country were due to the fact that the studies were small (sampling error) or whether they were true differences. In an earlier small-scale study in Frankfurt, we examined mortality during the first two years of the pandemic. Our aim was to continue this analysis until the end of 2023, for the first time taking into account other factors influencing mortality such as influenza and heat.
We obtained population data for Frankfurt am Main for 2016-2023 from the Municipal Office of Statistics, City of Frankfurt/Main, mortality data from 2016 to 2023 from the Hessian State Office for Health and Care, data on SARS-CoV-2 and influenza notifications from the homepage of the Robert Koch-Institute and weather data from the homepage of the German Meteorological Office. For calculating standardized mortality ratios (SMR= observed number of deaths divided by the expected number of deaths), we multiplied the mean mortality rate for 5 age groups from 2016-2019 with the total numer of residents in those age groups in the further years or periods, and finally added the numbers of expected deaths per age group.
The update of the assessment of mortality adjusted for age and population trend in the years 2020-2023 in Frankfurt am Main shows an excess mortality (SMR 1.029; 95% CI 1.004-1.054, +185 excess deaths) in 2022, followed by a negative excess mortality in 2023 (SMR 0.972; 95% CI 0.948-0.996). In the years 2020 and 2021 however, no increase in excess mortality had been found (2020: SMR 0.976; 95% CI 0.951-1.001; 2021: 0.998; 95% CI 0,973-1.023). In the second wave of the SARS CoV-2 pandemic with the Wuhan type (fall 2020), a significantly increased mortality was found (SMR 1.106; 95% CI 1.066-1.147, +274 deaths), as well as during the first four waves overall (Wuhan, Alpha and Delta type) (SMR 1.023; 95 CI 1.001-1.045), whereas no increased mortality occurred during the further waves with the Omikron variant in 2022 (SMR 0.988; 95% CI 0.963-1.014). The increased mortality in 2022 was associated with an influenza wave in the last 6 weeks of the year, which had led to a strong increase in mortality (SMR 1.250; 95% CI 1.170-1.330).
During the SARS-CoV-2 pandemic, significant excess mortality occurred in Frankfurt am Main only in the second wave at the end of 2020 before vaccination was introduced; in all other waves, no significant excess mortality was recorded. Overall, there was a non-significant negative excess mortality in Frankfurt am Main in 2020 and 2021 and a significant negative excess mortality in 2023. In 2022, however, a significant excess mortality was observed, which could not be attributed to SARS-CoV-2 but to a short, intense wave of influenza in the last 6 weeks at the end of that year, which had also led to a significant increase in mortality throughout Germany. This influenza wave was associated with an excess mortality rate in Frankfurt am Main, which was higher than in any wave of the SARS-CoV-2 pandemic in Frankfurt am Main. The number of excess deaths during that influenza waves was larger than the excess deaths during all SARS-CoV-2 waves altogether. This remarkable fact should be taken into account when dealing with the evaluation of the pandemic, a process which is increasingly beeing called for in many ways in Germany but is still pending.
许多国家都对2019冠状病毒病大流行期间的死亡率进行了研究。研究结果受到所选计算方法、对人口老龄化的调整以及所使用的参考期的强烈影响。规模较小的研究有时显示出一个国家内部存在相当大的差异,但尚不清楚一个国家内部的差异是由于研究规模小(抽样误差)还是真实差异。在法兰克福早期的一项小规模研究中,我们考察了大流行头两年的死亡率。我们的目标是将这一分析持续到2023年底,首次考虑影响死亡率的其他因素,如流感和高温。
我们从法兰克福市统计局获得了2016 - 2023年美因河畔法兰克福的人口数据,从黑森州卫生与护理办公室获得了2016年至2023年的死亡率数据,从罗伯特·科赫研究所的主页获得了2019冠状病毒病和流感通报数据,并从德国气象局的主页获得了天气数据。为了计算标准化死亡率(SMR = 观察到的死亡人数除以预期死亡人数),我们将2016 - 2019年5个年龄组的平均死亡率与后续年份或时期这些年龄组的居民总数相乘,最后将每个年龄组的预期死亡人数相加。
对美因河畔法兰克福2020 - 2023年按年龄和人口趋势调整后的死亡率评估更新显示,2022年出现超额死亡率(SMR 1.029;95%可信区间1.004 - 1.054,超额死亡185人),随后2023年出现负超额死亡率(SMR 0.972;95%可信区间0.948 - 0.996)。然而,在2020年和2021年,未发现超额死亡率增加(2020年:SMR 0.976;95%可信区间0.951 - 1.001;2021年:0.998;95%可信区间0.973 - 1.023)。在2020年秋季武汉型2019冠状病毒病大流行的第二波中,发现死亡率显著增加(SMR 1.106;95%可信区间1.066 - 1.147,死亡274人),以及在总体前四波(武汉、阿尔法和德尔塔型)中(SMR 1.023;95%可信区间1.001 - 1.045),而在2022年奥密克戎变异株的后续波次中未出现死亡率增加(SMR 0.988;95%可信区间0.963 - 1.014)。2022年死亡率增加与当年最后6周的流感波有关,这导致死亡率大幅上升(SMR 1.250;95%可信区间1.170 - 1.330)。
在2019冠状病毒病大流行期间,美因河畔法兰克福仅在2020年底引入疫苗接种前的第二波中出现显著的超额死亡率;在所有其他波次中,未记录到显著的超额死亡率。总体而言,美因河畔法兰克福在2020年和2021年有不显著的负超额死亡率,在2023年有显著的负超额死亡率。然而,在2022年,观察到显著的超额死亡率,这不能归因于2019冠状病毒病,而是由于当年年底最后6周的短时间、强烈流感波,这也导致德国全国死亡率显著上升。这一流感波与美因河畔法兰克福的超额死亡率相关,该超额死亡率高于美因河畔法兰克福2019冠状病毒病大流行的任何一波。该流感波期间的超额死亡人数大于所有2019冠状病毒病波次的超额死亡人数总和。在处理大流行评估时应考虑到这一显著事实,德国在许多方面越来越多地呼吁进行这一评估,但该评估仍悬而未决。